Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum IV Complexes as Potent Antitumor Agents
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00784 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Wei Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry and Pharmaceutical Analysis, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi 710032, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Proto-Oncogene Proteins c-mdm2, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fourth Military Medical University, Shaanxi Provincial Science and Technology Department.
Abstract (Originalsprache)
While a number of p53-MDM2 inhibitors have progressed into clinical trials for the treatment of cancer, their progression has been hampered by a variety of problems, including acquired drug resistance, dose-dependent toxicity, and limited clinical efficiency. To make more progress, we integrated the advantages of MDM2 inhibitors and platinum drugs to construct novel PtIV-RG7388 (a selective MDM2 inhibitor) complexes. Most complexes, especially 5a and 5b, displayed greatly improved antiproliferative activity against both wild-type and mutated p53 cancer cells. Remarkably, 5a exhibited potent in vivo tumor growth inhibition in the A549 xenograft model (66.5%) without apparent toxicity. It arrested the cell cycle at both the S phase and the G2/M phase and efficiently induced apoptosis via the synergistic effects of RG7388 and cisplatin. Altogether, PtIV-RG7388 complex 5a exhibited excellent in vitro and in vivo antitumor activities, highlighting the therapeutic potential of PtIV-RG7388 complexes as antitumor agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry and Pharmaceutical Analysis, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
- Faculty of Pharmacy, School of Food and Biological Engineering, Shaanxi University of Science and Technology, Xi'an, Shaanxi 710021, China.
ORCID-Profile: Ru Jiang, Shengzheng Wang
Förderung
- National Natural Science Foundation of China
- Fourth Military Medical University
- Shaanxi Provincial Science and Technology Department
Zitieren
APA
Liu, W., Ma, Y., He, Y., Liu, Y., Guo, Z., He, J., Han, X., Hu, Y., Li, M., Jiang, R., & Wang, S. (2024). Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum IV Complexes as Potent Antitumor Agents. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00784
Vancouver
Liu W, Ma Y, He Y, Liu Y, Guo Z, He J, et al. Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum IV Complexes as Potent Antitumor Agents. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00784
BibTeX
@article{Liu2024,
author = {Liu, Wei and Ma, Yi and He, Youyou and Liu, Yanhong and Guo, Zhongjie and He, Jin and Han, Xiaodong and Hu, Yujiao and Li, Muqiong and Jiang, Ru and Wang, Shengzheng},
title = {Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum IV Complexes as Potent Antitumor Agents},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00784}
}
EUVIMED